Obesity dropouts hurt Altimmune
The company’s value is cut in half as mid-stage data prove a let-down.
Morphic looks to justify “oral Entyvio” excitement
Big hopes have built behind Morphic’s MORF-057 in ulcerative colitis, and a key trial reads out imminently.
The sun sets on Exelixis’s pipeline in a product
After Cabometyx’s latest clinical setback Exelixis might have to turn to follow-on projects for future growth.
